Clinical Trial Search

Primary: Percentage Change in Volume of the Masseter Muscle From Baseline to 12 Weeks After Treatment With Botulinum Toxin A — 21.4 percentage reduction in masseter volume

Primary: Change From 6 Months to Baseline in Visual Analogue Scale (VAS) Pain After 15 Minutes of Sitting — -28.1 mm

Primary: Median Change in Visceral Adipose Tissue (VAT) Volume — -4.6 cm^2

Primary: Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg

Primary: Number of Participants Rated Very Much Improved on the Global Aesthetic Improvement Scale (GAIS) by Prinicple Investigator — 19 participants

Primary: Number of Participants With Chronic Myogenic Pain, TMJ Disoder, and Burning Mouth Syndrome — 72; 8; 37; 7 Participants

Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants

Primary: Effect of Drug Regimens on Serum Triglycerides. — 228.0; 230.4; 293.4; 290.0 mg/dL — p=0.94

Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244

Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049

Primary: Change From Baseline in Limb Fat at Week 48 — 392; -257 grams (g) — p=0.0014

Primary: Total Limb Fat Mass — 8.84; 9.13 kg

Primary: Number of Subjects With Serious Adverse Events (SAEs) — 6; 2 Participants

Primary: HIV Self-testing Knowledge — 3.24; 3.79 score on a scale

Primary: Post Booster Polio Neutralizing Antibody Titers — 1715; 976; 1249; 1328 antibody titers

Primary: Change From Baseline in Trunk-to-limb Fat Ratio as Measured by Dual Energy X-Ray Absortiometry (DEXA) at Week 48 — 0.02; -0.02; 0.02; -0.01 ratio — p=0.48

Primary: Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms…

Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30

Primary: Plasma Concentration of Tenofovir (TFV) — 0; 0; 0; 0 ng/mL

Primary: Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent — -0.25; -0.96 mg/kg lean body mass/min

Primary: Nasal Tip Projection — 0.601 ratio

Primary: Number of Participants Who Stated (by Self-report) That They Had Side Effects — 1; 0; 2; 1 participants

Primary: Change in Fat mtDNA Content — -169; 321 copies/cell

Primary: Prevalence of HIV Infection — 6 Participants

Primary: Changes in the Inflammatory Marker IL-6 — 42.5; 40.0; 39.3; 41.1 pg/mL

Primary: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels Between Baseline and Week 24 — 66 fold decrease in signal/cutoff ratio

Primary: Blinded Evaluations of First Impression — 7.35 score on a scale

Primary: Baseline-Adjusted Means for C-terminal Telopeptide of Collagen (CTx) Levels — 0.092; 0.297; 0.122; 0.331 ng/ml

Primary: Number of Participants With SAEs — 0; 0; 2; 0 Participants

Primary: Change in Most Bothersome Symptom (MBS) of Vaginal Atrophy — 0; 1; 8; 4 Participants